The week in pharma: action, reaction and insight – week to July 10, 2026

By Barbara Obstoj-Cardwell. Editor

Last week’s regulatory news saw the US Food and Drug Administration (FDA) accept Swiss biotech Pharmvaris’ new drug application (NDA) for deucrictibant for the treatment hereditary angioedema (HAE) attacks. The FDA also approved Sanofi’s Sarclisa Escensa. On the M&A front, US drugmaker Vertex announced a $10 billion takeover bid for Crinetics and its rare disease drug Palsonify. Also of note, the UK’s AstraZeneca released disappointing Phase III trial results for its Wainua in cardiopathy.